Hoffman, AJ; Nichols, DE. Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. J. Med. Chem., 1 Sep 1985, 28 (9), 1252–1255. 583 kB. https://doi.org/10.1021/jm00147a022 #2 NMR
Meyers-Riggs, B. Non-LSD ergoloids. countyourculture, countyourculture: rational exploration of the underground, 1 Dec 2011.
Watts, VJ; Mailman, RB; Lawler, CP; Neve, KA; Nichols, DE. LSD and structural analogs: Pharmacological evaluation at D1 dopamine receptors. Psychopharmacology, 1 Apr 1995, 118 (4), 401–409. 1.4 MB. https://doi.org/10.1007/BF02245940 #EthLAD
Brandt, SD; Kavanagh, PV; Westphal, F; Elliott, SP; Wallach, J; Stratford, A; Nichols, DE; Halberstadt, AL. Return of the lysergamides. Part III: Analytical characterization of N6-ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1-propionyl ETH-LAD (1P-ETH-LAD). Drug Test. Anal., 1 Oct 2017, 9 (10), 1641-1649. 1.2 MB. https://doi.org/10.1002/dta.2196
Brandt, SD; Kavanagh, PV; Twamley, B; Westphal, F; Elliott, SP; Wallach, J; Stratford, A; Klein, LM; McCorvy, JD; Nichols, DE; Halberstadt, AL. Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775). Drug Test. Anal., 1 Feb 2018, 10 (2), 310-322. 1.2 MB. https://doi.org/10.1002/dta.2222
EMCDDA. New drugs in Europe, 2016, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2017. 489 kB. #43
Nichols, DE. Psychedelics. Pharmacol. Rev., 1 Apr 2016, 68 (2), 264-355. 1.9 MB. https://doi.org/10.1124/pr.115.011478 Updated with published correction to Figure 4 (the α-methyl group was missing in the original)
Nichols, DE. DARK classics in chemical neuroscience: Lysergic acid diethylamide (LSD). ACS Chem. Neurosci., 17 Oct 2018, 9 (10), 2331–2343. 1.1 MB. https://doi.org/10.1021/acschemneuro.8b00043
Jacob, P; Shulgin, AT. Structure-activity relationships of the classic hallucinogens and their analogs. In Hallucinogens: An update. NIDA Research Monograph 146; Lin, GC; Glennon, RA, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office, Washington, DC, 1 Jan 1994; pp 74–91. 51 kB.
Shulgin, AT. Basic Pharmacology and Effects. In Hallucinogens. A Forensic Drug Handbook; Laing, R; Siegel, JA, Eds., Academic Press, London, 24 Apr 2003; pp 67–137. 6.3 MB.
Hoffman, AJ. Synthesis and pharmacological evaluation of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. Ph. D. Thesis, Purdue University, 1 Aug 1987. 9.3 MB. #2 NMR
Wagmann, L; Richter, LHJ; Kehl, T; Wack, F; Bergstrand, MP; Brandt, SD; Stratford, A; Maurer, HH; Meyer, MR. In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures. Anal. Bioanal. Chem., 1 Jul 2019, 411 (19), 4751-4763. 3.8 MB. https://doi.org/10.1007/s00216-018-1558-9 #16 MS
Heim, R. Synthesis and pharmacology of potent 5-HT2A receptor agonists with N-2-methoxybenzyl partial structure. SC. D. Thesis, Freie Universität, Berlin, 1 Jan 2004. 3.9 MB. #22 In German. MS,NMR,IR
McCorvy, JD. Mapping the binding site of the 5-HT2A receptor using mutagenesis and ligand libraries: Insights into the molecular actions of psychedelics. Ph. D. Thesis, Purdue University, 1 Jan 2012. 3.9 MB. #Eth-LAD
Tanaka, R; Kawamura, M; Hakamatsuka, T; Kikura-Hanajiri, R. Identification and analysis of LSD derivatives in illegal products as paper sheet. Yakugaku Zasshi, 1 Jan 2020, 140 (5), 739–750. 932 kB. https://doi.org/10.1248/yakushi.19-00230 #3 MS,NMR,UV,other
Flanagan, TW; Billac, GB; Landry, AN; Sebastian, MN; Cormier, SA; Nichols, CD. Structure–activity relationship analysis of psychedelics in a rat model of asthma reveals the anti-inflammatory pharmacophore. ACS Pharmacol. Transl. Sci., 9 Apr 2021, 4 (2), 488-502. 13.3 MB. https://doi.org/10.1021/acsptsci.0c00063 #ETH-LAD
Tanaka, R; Kawamura, M; Hakamatsuka, T; Kikura-Hanajiri, R. Identification of LSD derivatives, 1cP-LSD, MIPLA and 1B-LSD in illegal products as paper sheet. Yakugaku Zasshi, 1 Nov 2020, 140 (11), 1405–1413. 606 kB. https://doi.org/10.1248/yakushi.20-00124 #7 MS,NMR,UV
Cumming, P; Scheidegger, M; Dornbierer, D; Palner, M; Quednow, BB; Martin-Soelch, C. Molecular and functional imaging studies of psychedelic drug action in animals and humans. Molecules, 1 Jan 2021, 26 (9), 2451. 3.5 MB. https://doi.org/10.3390/molecules26092451 #27
Brandt, SD; Kavanagh, PV; Westphal, F; Pulver, B; Schwelm, HM; Whitelock, K; Stratford, A; Auwärter, V; Halberstadt, AL. Analytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P‐AL‐LAD. Drug Test. Anal., 29 May 2022, 14 (8), 1503-1518. 1.3 MB. https://doi.org/10.1002/dta.3281 #ETH-LAD GC,LC,MS,NMR
Pfaff, RC; Huang, X; Marona-Lewicka, D; Oberlender, R; Nichols, DE. Lysergamides revisited. In Hallucinogens: An update. NIDA Research Monograph 146; Lin, GC; Glennon, RA, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office, Washington, DC, 1 Jan 1994; pp 52–73. 181 kB. #Table 1 (Ethyl)